Arzerra: new leukaemia antibody

GlaxoSmithKline has launched a new biological treatment for chronic lymphocytic leukaemia (CLL).

Ofatumumab (Arzerra) is a fully human monoclonal antibody. Like rituximab, it is specific for the CD20 antigen found on B cells.

Ofatumumab was tested in a pivotal study in 154 patients with CLL, a type of B cell tumour. Among the 59 participants who were refractory to fludarabine and alemtuzumab, 58% responded to ofatumumab treatment. Response rates were comparable between those who had previously received rituximab and those who had not.

Arzerra has been conditionally approved by the European Medicines Agency; therefore, the agency will review any new data on the product annually.

View Arzerra drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Avoid routinely offering antidepressants for 'less severe' depression, says NICE in draft guidance
Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Intal asthma inhaler to be discontinued

Intal asthma inhaler to be discontinued

The asthma preventer inhaler Intal (sodium cromoglicate)...